In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

“The only therapeutic vaccine that's approved is Provenge (sipuleucel-T) which is a completely different mechanism so we don't know whether this particular oncolytic viral approach will have ...

Currently, only one personalized cancer vaccine has been approved by the Food and Drug Administration (FDA) for use in the United States: Provenge (sipuleucel-T) for prostate cancer. Specifically ...

Objective: To review the activity of 3 new agents approved for the management of advanced castration-resistant prostate cancer (CRPC): sipuleucel-T, cabazitaxel, and abiraterone acetate.

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

It’s been 13 years since the FDA approved its first therapeutic vaccine – Dendreon Pharma’s Provenge (sipuleucel-T) for prostate cancer, which was not a commercial success – and since then ...

One therapeutic cancer vaccine that has remained in development is sipuleucel-T (Provenge; Dendreon) (Table 1), which was widely expected to receive approval in 2007 following a positive vote from ...